Clinical trials: Patients With Thyroid Cancer
Head and Neck Cancer
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: Phase II trial to study the effectiveness of gefitinib in treating patients who have locally advanced or…
- Trial name
- NCT00095836
- Testing
- Gefitinib
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Massachusetts General Hospital
Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed.
- Conditions
- Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma, Central Nervous System Neoplasm, Childhood Clear Cell Sarcoma of Soft Tissue
- Trial name
- NCT02867592
- Testing
- Cabozantinib, Cabozantinib S-malate, Pharmacological Study
- Where
- 142 sites in United States
- Volunteers
- 109 people
- Sponsor
- National Cancer Institute (NCI)
Thyroid Neoplasms, Poorly Differentiated and Undifferentiated Thyroid Cancer
CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer
Background: The thyroid is a gland at the base of the throat. Thyroid cancer is a disease that people get when abnormal cells begin to grow in this gland.
- Conditions
- Thyroid Neoplasms, Poorly Differentiated and Undifferentiated Thyroid Cancer, Differentiated Thyroid Cancer
- Trial name
- NCT03002623
- Testing
- CUDC-907
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma
Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma
Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/day in Japanese Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma.
- Trial name
- NCT01661179
- Testing
- Vandetanib 300mg
- Where
- 4 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Genzyme, a Sanofi Company
Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer
Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
This phase II trial is studying how well tanespimycin works in treating patients with inoperable locoregionally advanced or metastatic thyroid cancer.
- Conditions
- Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer, Thyroid Gland Medullary Carcinoma
- Trial name
- NCT00118248
- Testing
- tanespimycin
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Medullary Thyroid Cancer
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that…
- Trial name
- LIBRETTO-531 (NCT04211337)
- Testing
- Selpercatinib, Cabozantinib, Vandetanib
- Where
- 143 sites in United States, Australia and 18 more
- Volunteers
- 291 people
- Sponsor
- Loxo Oncology, Inc.
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
This phase II MATCH treatment trial identifies the effects of trametinib and dabrafenib in patients whose cancer has genetic changes called BRAF V600 mutations.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439292
- Testing
- Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Thyroid Neoplasms
Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer
This was a parallel group, randomized, double blind, placebo controlled, multicentre study designed to assess whether vandetanib (ZD6474) conferred an improvement in PFS as compared to placebo in participants with locally…
- Trial name
- NCT00537095
- Testing
- Vandetanib
- Where
- 15 sites in Belgium, Denmark and 5 more
- Volunteers
- 164 people
- Sponsor
- Genzyme, a Sanofi Company
Recurrent Thyroid Gland Carcinoma, Stage I Thyroid Gland Papillary Carcinoma
Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine
This phase II trial is studying how well selumetinib works in treating patients with papillary thyroid cancer that did not respond to radioactive iodine.
- Conditions
- Recurrent Thyroid Gland Carcinoma, Stage I Thyroid Gland Papillary Carcinoma, Stage II Thyroid Gland Papillary Carcinoma, Stage III Thyroid Gland Papillary Carcinoma
- Trial name
- NCT00559949
- Testing
- Laboratory Biomarker Analysis, Selumetinib
- Where
- 6 sites in United States, Canada
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Trial name
- LIBRETTO-001 (NCT03157128)
- Testing
- LOXO-292
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 857 people
- Sponsor
- Eli Lilly and Company
Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
This phase II trial studies how well trametinib works in increasing tumoral iodine incorporation in patients with thyroid cancer that has come back or spread to another place in the body.
- Conditions
- Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma
- Trial name
- NCT02152995
- Testing
- Computed Tomography, Iodine I 124, Iodine I-131
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Thyroid Cancer, Postsurgical Hypothyroidism
Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy
In some patients, levothyroxine liquid gel capsules may demonstrate superior absorption than the tablet option. Impaired absorption of thyroid hormone directly correlates to higher and more unpredictable TSH (thyroid stimulating…
- Trial name
- NCT02946918
- Testing
- Levothyroxine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Texas Southwestern Medical Center
Ovarian Cancer, Cervical Cancer
Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors
The purpose of the trial is to determine the maximum tolerated dose and to establish the safety profile of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors
- Conditions
- Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Non Small Cell Lung Cancer (NSCLC)
- Trial name
- NCT02988817
- Testing
- Enapotamab vedotin (HuMax-AXL-ADC)
- Where
- 41 sites in United States, Belgium and 4 more
- Volunteers
- 306 people
- Sponsor
- Genmab
Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
This phase II trial studies how well sunitinib malate works in treating patients with thyroid cancer that did not respond to iodine I 131 (radioactive iodine) and cannot be removed by surgery.
- Conditions
- Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Stage III Thyroid Gland Follicular Carcinoma AJCC v7
- Trial name
- NCT00381641
- Testing
- Laboratory Biomarker Analysis, Pharmacogenomic Study, Sunitinib
- Where
- 17 sites in United States
- Volunteers
- 63 people
- Sponsor
- National Cancer Institute (NCI)
Medullary Thyroid Cancer
An Initial Study of Lithium in Patients With Medullary Thyroid Cancer
Primary objective is to evaluate the tumor response rate of patients with MTC treated with Lithium carbonate
- Trial name
- NCT00582712
- Testing
- Lithium carbonate
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Thyroid Carcinoma, Thyroidectomy
Efficacy of Fibrin Sealant to Reduce the Amount of Post-thyroidectomy Drain
Fibrin sealant has been studied to reduce post-thyroidectomy drain and hospital stay as well. However, no strong evidence from well-designed clinical trials is available.
- Trial name
- NCT01126060
- Testing
- Usage of Fibrin sealant, Thyroidectomy
- Where
- South Korea
- Volunteers
- 78 people
- Sponsor
- Samsung Medical Center
Healthy, Pituitary Disease
Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities
This study will determine the safety and activity of a new formulation of thyrotropin-releasing hormone (TRH), a drug used for diagnosing and evaluating patients with certain thyroid gland abnormalities.
- Conditions
- Healthy, Pituitary Disease, Thyroid Disease
- Trial name
- NCT00054756
- Testing
- TRH (Thyrotropin Releasing Hormone)
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)